191 related articles for article (PubMed ID: 25211658)
1. New insights into signalling-pathway alterations in rhabdomyosarcoma.
Zhu B; Davie JK
Br J Cancer; 2015 Jan; 112(2):227-31. PubMed ID: 25211658
[TBL] [Abstract][Full Text] [Related]
2. Uncovering metabolism in rhabdomyosarcoma.
Monti E; Fanzani A
Cell Cycle; 2016; 15(2):184-95. PubMed ID: 26209235
[TBL] [Abstract][Full Text] [Related]
3. Epigenetically upregulated GEFT-derived invasion and metastasis of rhabdomyosarcoma via epithelial mesenchymal transition promoted by the Rac1/Cdc42-PAK signalling pathway.
Liu C; Zhang L; Cui W; Du J; Li Z; Pang Y; Liu Q; Shang H; Meng L; Li W; Song L; Wang P; Xie Y; Wang Y; Liu Y; Hu J; Zhang W; Li F
EBioMedicine; 2019 Dec; 50():122-134. PubMed ID: 31761617
[TBL] [Abstract][Full Text] [Related]
4. Failure to downregulate the BAF53a subunit of the SWI/SNF chromatin remodeling complex contributes to the differentiation block in rhabdomyosarcoma.
Taulli R; Foglizzo V; Morena D; Coda DM; Ala U; Bersani F; Maestro N; Ponzetto C
Oncogene; 2014 May; 33(18):2354-62. PubMed ID: 23728344
[TBL] [Abstract][Full Text] [Related]
5. Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma.
Sun W; Chatterjee B; Shern JF; Patidar R; Song Y; Wang Y; Walker RL; Pawel BR; Linardic CM; Houghton P; Hewitt SM; Edelman DC; Khan J; Meltzer PS; Barr FG
Int J Cancer; 2019 Jun; 144(11):2707-2717. PubMed ID: 30565669
[TBL] [Abstract][Full Text] [Related]
6. IL-4R drives dedifferentiation, mitogenesis, and metastasis in rhabdomyosarcoma.
Hosoyama T; Aslam MI; Abraham J; Prajapati SI; Nishijo K; Michalek JE; Zarzabal LA; Nelon LD; Guttridge DC; Rubin BP; Keller C
Clin Cancer Res; 2011 May; 17(9):2757-66. PubMed ID: 21536546
[TBL] [Abstract][Full Text] [Related]
7. The ablation of EZH2 uncovers its crucial role in rhabdomyosarcoma formation.
Marchesi I; Fiorentino FP; Rizzolio F; Giordano A; Bagella L
Cell Cycle; 2012 Oct; 11(20):3828-36. PubMed ID: 22983009
[TBL] [Abstract][Full Text] [Related]
8. Testosterone-mediated activation of androgenic signalling sustains in vitro the transformed and radioresistant phenotype of rhabdomyosarcoma cell lines.
Giannattasio S; Megiorni F; Di Nisio V; Del Fattore A; Fontanella R; Camero S; Antinozzi C; Festuccia C; Gravina GL; Cecconi S; Dominici C; Di Luigi L; Ciccarelli C; De Cesaris P; Riccioli A; Zani BM; Lenzi A; Pestell RG; Filippini A; Crescioli C; Tombolini V; Marampon F
J Endocrinol Invest; 2019 Feb; 42(2):183-197. PubMed ID: 29790086
[TBL] [Abstract][Full Text] [Related]
9. TBX2 represses PTEN in rhabdomyosarcoma and skeletal muscle.
Zhu B; Zhang M; Williams EM; Keller C; Mansoor A; Davie JK
Oncogene; 2016 Aug; 35(32):4212-24. PubMed ID: 26686089
[TBL] [Abstract][Full Text] [Related]
10. Alternative splicing of MEF2C pre-mRNA controls its activity in normal myogenesis and promotes tumorigenicity in rhabdomyosarcoma cells.
Zhang M; Zhu B; Davie J
J Biol Chem; 2015 Jan; 290(1):310-24. PubMed ID: 25404735
[TBL] [Abstract][Full Text] [Related]
11. Expression and parental imprinting of the H19 gene in human rhabdomyosarcoma.
Casola S; Pedone PV; Cavazzana AO; Basso G; Luksch R; d'Amore ES; Carli M; Bruni CB; Riccio A
Oncogene; 1997 Mar; 14(12):1503-10. PubMed ID: 9136994
[TBL] [Abstract][Full Text] [Related]
12. Novel small molecule DMAMCL induces differentiation in rhabdomyosarcoma by downregulating of DLL1.
Li Q; Chen Y; Chen Y; Hua Z; Gong B; Liu Z; Thiele CJ; Li Z
Biomed Pharmacother; 2024 May; 174():116562. PubMed ID: 38626518
[TBL] [Abstract][Full Text] [Related]
13. Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses.
Stewart E; McEvoy J; Wang H; Chen X; Honnell V; Ocarz M; Gordon B; Dapper J; Blankenship K; Yang Y; Li Y; Shaw TI; Cho JH; Wang X; Xu B; Gupta P; Fan Y; Liu Y; Rusch M; Griffiths L; Jeon J; Freeman BB; Clay MR; Pappo A; Easton J; Shurtleff S; Shelat A; Zhou X; Boggs K; Mulder H; Yergeau D; Bahrami A; Mardis ER; Wilson RK; Zhang J; Peng J; Downing JR; Dyer MA;
Cancer Cell; 2018 Sep; 34(3):411-426.e19. PubMed ID: 30146332
[TBL] [Abstract][Full Text] [Related]
14. miR-203, a tumor suppressor frequently down-regulated by promoter hypermethylation in rhabdomyosarcoma.
Diao Y; Guo X; Jiang L; Wang G; Zhang C; Wan J; Jin Y; Wu Z
J Biol Chem; 2014 Jan; 289(1):529-39. PubMed ID: 24247238
[TBL] [Abstract][Full Text] [Related]
15. DNA repair systems in rhabdomyosarcoma.
Tsioli PG; Patsouris ES; Giaginis C; Theocharis SE
Histol Histopathol; 2013 Aug; 28(8):971-84. PubMed ID: 23516236
[TBL] [Abstract][Full Text] [Related]
16. Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice.
Nanni P; Nicoletti G; De Giovanni C; Croci S; Astolfi A; Landuzzi L; Di Carlo E; Iezzi M; Musiani P; Lollini PL
Cancer Res; 2003 Jun; 63(11):2728-32. PubMed ID: 12782574
[TBL] [Abstract][Full Text] [Related]
17. Genetic Characterization, Current Model Systems and Prognostic Stratification in PAX Fusion-Negative vs. PAX Fusion-Positive Rhabdomyosarcoma.
Dehner CA; Armstrong AE; Yohe M; Shern JF; Hirbe AC
Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680895
[TBL] [Abstract][Full Text] [Related]
18. Defining the gene expression signature of rhabdomyosarcoma by meta-analysis.
Romualdi C; De Pittà C; Tombolan L; Bortoluzzi S; Sartori F; Rosolen A; Lanfranchi G
BMC Genomics; 2006 Nov; 7():287. PubMed ID: 17090319
[TBL] [Abstract][Full Text] [Related]
19. TBX2 blocks myogenesis and promotes proliferation in rhabdomyosarcoma cells.
Zhu B; Zhang M; Byrum SD; Tackett AJ; Davie JK
Int J Cancer; 2014 Aug; 135(4):785-97. PubMed ID: 24470334
[TBL] [Abstract][Full Text] [Related]
20. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
